PhotoMedex to Present at the Rodman & Renshaw 8th Annual Healthcare Conference

Nov 01, 2006, 00:00 ET from PhotoMedex, Inc.

    MONTGOMERYVILLE, Pa., Nov. 1 /PRNewswire-FirstCall/ -- PhotoMedex, Inc.
 (Nasdaq:   PHMD) announced today that it is scheduled to make an investor
 presentation at the Rodman & Renshaw 8th Annual Healthcare Conference at
 9:10 a.m. EST on Monday, November 6, 2006. The conference is being held at
 the New York Palace Hotel, 455 Madison Avenue, (between 50th and 51st
 Streets) New York, NY.
     A live webcast of the Company's presentation at the Conference will be
 available by going to and clicking on the link to
 Investor Relations. An archived replay will be available for a period of 90
     About PhotoMedex
     PhotoMedex is engaged in the development of proprietary excimer laser
 and fiber optic systems and techniques directed toward dermatological
 applications, with FDA 510(k) clearances to market the XTRAC(R) laser
 system for the treatment of psoriasis, vitiligo, atopic dermatitis and
 leukoderma. In addition, the Company provides contract medical procedures
 to hospitals, surgi-centers and doctors' offices, offering a wide range of
 products and services across multiple specialty areas, including
 dermatology, urology, gynecology, orthopedics, and other surgical
 specialties. The Company is a leader in the development, manufacturing and
 marketing of medical laser products and services. In addition, as a result
 of the merger with ProCyte, PhotoMedex now develops and markets products
 based on its patented, clinically proven Copper Peptide technology for skin
 health, hair care and wound care. PhotoMedex sells directly to
 dermatologists, plastic and cosmetic surgeons, spas and salons and through
 licenses with strategic partners into the consumer market, including a
 long-term worldwide license agreement with Neutrogena(R), a Johnson &
 Johnson company. ProCyte brands include Neova(R), Ti-Silc(R),
 VitalCopper(R), Simple Solutions(R) and AquaSante(R).
     Some paragraphs of this press release, particularly those describing
 PhotoMedex' strategies, contain forward-looking statements within the
 meaning of Section 27A of the Securities Act of 1993, as amended, and
 Section 21E of the Securities Exchange Act of 1934, as amended. While
 PhotoMedex is working to achieve those goals and strategies, actual results
 could differ materially from those projected in the forward-looking
 statements as a result of a number of factors, including difficulties in
 marketing its products and services, need for capital, competition from
 other companies and other factors, any of which could have an adverse
 effect on the business plans of PhotoMedex, its reputation in the industry
 or its expected financial return from operations. Factors such as these
 could have an adverse effect on PhotoMedex' results of operations. In light
 of significant uncertainties inherent in forward-looking statements
 included herein, the inclusion of such statements should not be regarded as
 a representation by PhotoMedex and its subsidiaries that they will achieve
 such forward-looking statements.
     Contacts:  Allen & Caron                 PhotoMedex, Inc.
                Matt Clawson (investors)      Dennis McGrath, CFO
                949-474-4300                  215-619-3287

SOURCE PhotoMedex, Inc.